AbbVie climbs on new immunology drug sales
Pharmaceutical company Abbvie’s share price rose in early trading after it reported better-than-expected earnings and upbeat 2025 guidance, with newer drugs delivering growth.
Overall, the company brought in $15 billion in revenue and $3.7 billion in profit in the last three months of 2024. It also set its 2025 guidance at $12.12 to $12.32 a share, compared to the $12.15 a share analysts polled by FactSet expected.
AbbVie’s largest segment, immunology, was able to keep its sales growing even after its patent for Humira, its blockbuster autoimmune drug, expired in 2023. The company’s newer immunology drugs, Skyrizi and Rinvoq, have offset the decline in sales of Humira. The patents for Skyrizi and Rinvoq expire in 2032 and 2033, respectively.
AbbVie’s largest segment, immunology, was able to keep its sales growing even after its patent for Humira, its blockbuster autoimmune drug, expired in 2023. The company’s newer immunology drugs, Skyrizi and Rinvoq, have offset the decline in sales of Humira. The patents for Skyrizi and Rinvoq expire in 2032 and 2033, respectively.
